Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Analysts

Posted by Geri Gentry on Aug 8th, 2026

Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) has been given an average rating of “Hold” by the four analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $27.50.

A number of analysts recently issued reports on the stock. Wall Street Zen lowered shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fulgent Genetics in a report on Monday, July 6th. Finally, Piper Sandler increased their price target on Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday.

View Our Latest Research Report on FLGT

Fulgent Genetics Price Performance

Shares of NASDAQ:FLGT opened at $19.14 on Friday. Fulgent Genetics has a 12 month low of $13.46 and a 12 month high of $31.04. The firm has a market capitalization of $526.54 million, a price-to-earnings ratio of -6.79 and a beta of 0.90. The business’s 50 day simple moving average is $19.37 and its 200-day simple moving average is $18.90.

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). The business had revenue of $85.39 million for the quarter, compared to analysts’ expectations of $94.00 million. Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. On average, equities analysts anticipate that Fulgent Genetics will post -2.81 earnings per share for the current year.

Insider Activity at Fulgent Genetics

In other Fulgent Genetics news, COO Jian Xie sold 2,146 shares of Fulgent Genetics stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $38,391.94. Following the transaction, the chief operating officer owned 367,605 shares in the company, valued at $6,576,453.45. This trade represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $30,198.32. Following the completion of the transaction, the insider directly owned 990,374 shares in the company, valued at $17,717,790.86. This trade represents a 0.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,980 shares of company stock worth $106,360 over the last three months. Corporate insiders own 36.18% of the company’s stock.

Institutional Investors Weigh In On Fulgent Genetics

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Fulgent Genetics in the 2nd quarter valued at $46,922,000. Northwestern Mutual Wealth Management Co. boosted its position in Fulgent Genetics by 2,984,354.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock worth $39,985,000 after purchasing an additional 1,522,021 shares during the period. Millennium Management LLC increased its holdings in Fulgent Genetics by 1.8% in the 3rd quarter. Millennium Management LLC now owns 1,468,844 shares of the company’s stock valued at $33,196,000 after purchasing an additional 26,582 shares in the last quarter. Vanguard Group Inc. increased its holdings in Fulgent Genetics by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,179,254 shares of the company’s stock valued at $26,651,000 after purchasing an additional 13,295 shares in the last quarter. Finally, RTW Investments LP purchased a new position in Fulgent Genetics in the fourth quarter valued at about $18,521,000. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.